



ELSEVIER

Contents lists available at ScienceDirect

## Preventive Medicine

journal homepage: [www.elsevier.com/locate/ypmed](http://www.elsevier.com/locate/ypmed)

# Prevalence, Trends, and Distribution of Nicotine and Marijuana use in E-cigarettes among US adults: The Behavioral Risk Factor Surveillance System 2016–2018

S. M. Iftexhar Uddin<sup>a,b</sup>, Albert D. Osei<sup>a,b</sup>, Olufunmilayo H. Obisesan<sup>a,b</sup>, Omar El-Shahawy<sup>a,c</sup>, Omar Dzaye<sup>b</sup>, Miguel Cainzos-Achirica<sup>b</sup>, Mohammadhassan Mirbolouk<sup>b,d</sup>, Olusola A. Orimoloye<sup>b,e</sup>, Andrew Stokes<sup>a,f</sup>, Emelia J. Benjamin<sup>a,f</sup>, Aruni Bhatnagar<sup>a,g</sup>, Andrew P. DeFilippis<sup>a,g</sup>, Travis S. Henry<sup>h</sup>, Khurram Nasir<sup>b,i</sup>, Michael J. Blaha<sup>a,b,\*</sup>

<sup>a</sup> The American Heart Association Tobacco Regulation and Addiction Center, Dallas, TX, United States of America

<sup>b</sup> Johns Hopkins University, Baltimore, MD, United States of America

<sup>c</sup> New York University, New York City, NY, United States of America

<sup>d</sup> Yale New Haven Hospital, New Haven, CT, United States of America

<sup>e</sup> Vanderbilt University Medical Center, Nashville, TN, United States of America

<sup>f</sup> Boston University, Boston, MA, United States of America

<sup>g</sup> University of Louisville, Louisville, KY, United States of America

<sup>h</sup> University of California, San Francisco, San Francisco, CA, United States of America

<sup>i</sup> Houston Methodist Hospital, Houston, TX, United States of America

## ARTICLE INFO

## Keywords:

Electronic cigarettes  
Tobacco  
Marijuana  
Vaping  
EVALI  
Prevalence  
Surveys

## ABSTRACT

Use of substances other than nicotine in e-cigarettes, especially marijuana, is becoming increasingly popular in the US. However, population-representative data on such poly-use (nicotine and marijuana) remains limited. We therefore conducted a cross-sectional logistic regression analysis of the 2018 Behavioral Risk Factor Surveillance System among 16 US states/territories with data on past 30-day marijuana use to describe the emerging dual nicotine and marijuana vaping population. We additionally examined trends in marijuana use, including marijuana vaping, from 2016 to 2018.

Of the 131,807 participants studied, 3068 were current e-cigarette users, among whom 7.1% also vaped marijuana. Prevalence of nicotine-predominant, dual nicotine marijuana, and marijuana-predominant vaping was 3.36%, 0.38% and 1.09%, respectively. Compared to nicotine-predominant vapers, dual and marijuana-predominant vapers were older, had greater proportions of non-Whites, particularly Hispanics, and less likely to be current smokers (nicotine-predominant vs dual vs marijuana-predominant vaping: current tobacco use 44.7 vs 23.7 vs 11.1%). Proportion of dual vapers among current e-cigarette users was 8.6%, 2.6% and 7.1% for 2016, 2017 and 2018, respectively. Prevalence of marijuana use increased from 8.97% (2016) to 13.1% (2018) while no clear trend was observed for marijuana vaping.

Dual nicotine and marijuana vaping is prevalent in the US, and compared to predominantly nicotine vapers such users have higher mean ages, and are more likely to be Blacks, Hispanics, and never cigarette smokers. Marijuana use overall increased from 2016 to 2018. Dual vapers represent a large and important emerging population that will require dedicated study of health effects and tailored regulatory strategies.

## 1. Introduction

Electronic cigarettes (e-cigarettes) are battery-powered devices that deliver aerosol to users by heating a solution typically containing nicotine, flavors, and other chemicals. E-cigarettes are one of the most

popular tobacco products in the US (Mirbolouk et al., 2016; Office of the Surgeon General, 2016). Their popularity and appeal especially among youth and young adults, including among those who previously did not smoke cigarettes, have made e-cigarettes an important public health concern (National Academies of Sciences, Engineering and M,

\* Corresponding author at: Blalock 524D1, Johns Hopkins Hospital, 600 N. Wolfe St, Baltimore, MD 21287, United States of America.

E-mail address: [mblaha1@jhmi.edu](mailto:mblaha1@jhmi.edu) (M.J. Blaha).

<https://doi.org/10.1016/j.ypmed.2020.106175>

Received 10 January 2020; Received in revised form 19 June 2020; Accepted 20 June 2020

Available online 25 June 2020

0091-7435/ © 2020 Elsevier Inc. All rights reserved.

2018). Due to the evolving epidemiology of e-cigarettes, it is crucial to monitor changes in their use patterns. An emerging pattern seen among a subpopulation of vapers is the use of substances besides nicotine in e-cigarettes. Such substances include vaping alcohol, marijuana, and herbs and supplements, with marijuana and alcohol being the most popular (Basáñez et al., 2019; Kenne et al., 2017). For instance, around 7% of e-cigarette users in a university population were found to have used substances other than nicotine in their e-cigarettes, the majority of whom used marijuana (78%) (Kenne et al., 2017). Additionally, a 2017 study of US adults aged  $\geq 18$  years reported that a substantial 4.7% of adults reported vaping marijuana in the previous year (Steigerwald et al., 2018).

In June–November 2019, there was an outbreak of over 2500 e-cigarette, or vaping, product use associated lung injury (EVALI) cases across the US. Concerningly, most of the cases were reported to have used marijuana-related products or a poly-use of marijuana and nicotine in their e-cigarettes. (Centers for Disease Control and Prevention, 2019; Layden et al., 2019; Maddock et al., 2019) The outbreak prompted the Centers for Disease Control and Prevention (CDC) to issue a Health Advisory alert and take an unprecedented step of recommending refraining from e-cigarette use particularly for youth, young adults, pregnant women, and non-cigarette smoking adults. (CDC Health Alert Network, 2019) The EVALI outbreak underscores the potential dangers of e-cigarette use and highlights a crucially-needed focus on an emerging marijuana vaping population.

The increasing legalization of marijuana across the US, in addition to the rapid rise in overall e-cigarette use, mandates study of a new subpopulation of dual marijuana and e-cigarette users. There is however paucity of data on the size and characteristics of such a ‘dual vaping’ population, and the marijuana vaping population in general. Individuals vaping marijuana may be different from conventional nicotine vapers and may therefore need tailored health education, health promotion, and other preventive interventions.

Therefore, using the largest and most contemporary US survey of e-cigarette use to date, the Behavioral Risk Factor Surveillance System (BRFSS), we sought to (1) Describe the size and characteristics of the emerging dual nicotine and marijuana vaping population, and (2) Examine trends in marijuana use in the US from 2016 to 2018, with a particular focus on marijuana vaping.

## 2. Methods

### 2.1. Study design and setting

For the primary cross-sectional descriptive analysis, we used data from 2018, the most up to date cycle of BRFSS. The BRFSS is an extensive, nationally representative telephone survey conducted by the CDC jointly with all the states and participating territories of the US. For the analysis of trends, we additionally used data from 2016, 2017 and 2018 BRFSS. All analyses focused on the states and territories for which marijuana data was available for each year; 12 states/territories provided data in 2016 and 2017 and 16 states/territories provided data in 2018. Since different number of states provided marijuana data over the 3 years, we focused the trends analysis primarily on the six states that provided marijuana data for each of the 3 years. These consistent states were California, Idaho, Minnesota, Oklahoma, Tennessee and Wyoming. These states/territories had varying legal statuses on marijuana use and are described in Supplemental Tables 3 and 4. The median survey response rate for all states and territories for the 2018 BRFSS was 53.3% for landline telephone and 43.4% for cell phone, and the overall combined median response rate was 49.9%. Response rates for BRFSS are calculated using the response rate formula of the American Association for Public Opinion Research.

### 2.2. Study population and E-cigarette and Marijuana use assessment

We included 131,807 participants aged 18 years or older from the 2018 BRFSS. To assess e-cigarette use, participants were asked, “Have you ever used an e-cigarette or other electronic ‘vaping’ product, even just one time, in your entire life?”. Those who answered yes were then asked a second question: “Do you now use e-cigarettes or other electronic ‘vaping’ products every day, some days, or not at all?”. Participants who responded “every day” and “some days” were considered current e-cigarette users.

For 2017 and 2018 BRFSS, the (nicotine) e-cigarette question included a note for interviewer specifically on nicotine and marijuana: “Interviewer note: These questions concern electronic vaping products for nicotine use. The use of electronic vaping products for marijuana use is not included in these questions.”. For 2016 BRFSS, however, this note was not included, possibly because poly-substance use in e-cigarettes was not as common at the time.

To assess marijuana use, participants were asked, “During the past 30 days, on how many days did you use marijuana or cannabis?”. Those who responded any use were then asked, “During the past 30 days, which one of the following ways did you use marijuana the most often?”. Participants who responded affirmatively to the option “Vaporize it (for example, in an e-cigarette-like vaporizer or another vaporizing device)” were considered marijuana vapers. This included participants who used marijuana via vaping only, and those who vaped marijuana in addition to using via other modes (such as smoking, eating, drinking, and dabbing).


Participants who were current e-cigarette users and who also vaped marijuana were considered “dual vapers”. Conversely, those who were current e-cigarette users and did not vape marijuana were considered “nicotine-predominant vapers”. Those who were marijuana vapers and were not dually vaping nicotine were considered as “marijuana-predominant” vapers. We chose the “predominant” label since it is possible that participants might have used other substances besides nicotine/marijuana in their e-cigarettes.

### 2.3. Study variables

Key demographic and socioeconomic variables included age, sex, race/ethnicity, education, and income level. Health-related characteristics included depression, BMI and smoking status. Household income was reported according to the federal poverty guidelines of 2018, taking into consideration the number of persons in family/household (U.S. Department of Health & Human Services, 2018). Depression was defined as a history of clinical diagnosis if participants responded yes to the question, “Has a physician ever told you have a depressive disorder (including depression, major depression, dysthymia, or minor depression)?” Body mass index (BMI) was calculated using reported height and weight. Smoking status was categorized as current, former and never. All variables were self-reported.

### 2.4. Statistical analysis

We first merged the core and optional BRFSS datasets according to the BRFSS marijuana analytic module for the 16 states with data on marijuana use for 2018 (Behavioral Risk Factor Surveillance System, 2016; Behavioral Risk Factor Surveillance System (BRFSS), 2019). We calculated the weighted prevalence of current e-cigarette use and marijuana vaping according to the 2018 BRFSS analytic guidelines (Behavioral Risk Factor Surveillance System, 2018). For prevalence calculations by sociodemographic sub-groups, participants with missing information on the sub-group of interest were excluded. We generated estimates of the number of nicotine and marijuana vapers in the US by applying nationally-representative prevalence estimates to US Census Bureau’s projection of number of adults in 2018 (National KIDS COUNT, 2019; U.S. Census Bureau, 2018). We conducted multivariable



**Fig. 1.** Schema showing the three sub-populations in the study: nicotine-predominant vapers (gold), dual nicotine and marijuana vapers (orange) and marijuana-predominant vapers (light orange).

**Note.** Not to scale. Counts and weighted prevalence: Nicotine-predominant vapers, 2904 (3.36%); dual nicotine marijuana vapers 164 (0.38%); Marijuana-predominant vapers 570 (1.09%). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

logistic regression analyses comparing factors associated with (1) Dual vaping (vs nicotine-predominant vaping) and (2) Marijuana-predominant vaping (vs nicotine-predominant vaping). The following covariates were included in all the models: age, sex, race, education, poverty level, clinical depression, BMI and smoking status. We used the `svy` command to account for the complex survey design. Marijuana use prevalence was analyzed by year and absolute differences in prevalence were calculated with the `lincom` command. All analyses were performed using Stata v14.2 (Statacorp, College Station, TX).

**3. Results**

We included a total of 131,807 BRFSS participants aged 18 years or older from the 2018 BRFSS. Median age category of the current e-cigarette using population was 35–39 years. Additionally, 41.4% of the population were females. The prevalence of current e-cigarette use was 5.4% (95% CI, 5.0–5.8%). Median age category of marijuana vapers was 40–44 years and 38.5% were females. The prevalence of marijuana vaping was 1.3% (95% CI, 1.2–1.5%).

Fig. 1 shows the 3 populations examined in the study. There was a total of 2904 current e-cigarette users who were nicotine-predominant vapers, and 164 current e-cigarette users who also vaped marijuana (dual nicotine marijuana vapers). Dual vapers thus made up 7.1% (weighted proportion) of the current e-cigarette user population. Additionally, there was a total of 734 marijuana vapers, which was comprised of 164 aforementioned dual vapers and 570 marijuana-predominant vapers. The prevalence of the 3 populations were as follows: nicotine-predominant vapers (3.36%); dual nicotine marijuana vapers (0.38%) and marijuana-predominant vapers (1.09%).

Table 1 shows the sociodemographic and health-related characteristics of the three groups. Adults in the 18–24 year age group made up 17.2% and 18.3% in the dual and marijuana-predominant vaping population, respectively, compared to 33.2% in the nicotine-predominant population. Approximately 19.7% of dual vapers were 45–69-years old, compared to 30.7% of marijuana-predominant vapers in the same age category.

Males constituted the majority of vapers in all three populations. Similarly, adults with some college education and those with family income greater than the poverty level constituted the majority of all three populations, which was even more pronounced in the dual and marijuana-predominant vaping populations. Though Whites made up the largest racial/ethnicity group in the three populations, dual and marijuana-predominant vapers had greater proportions of non-Whites – particularly Hispanics – compared to nicotine-predominant vapers.

**Table 1**

Sociodemographic and health-related characteristics among nicotine-predominant, dual nicotine and marijuana and marijuana-predominant e-cigarette users in the US, 2018.

	Nicotine-predominant vaping (Unweighted n = 2904)	Dual nicotine marijuana vaping (Unweighted n = 164)	Marijuana-predominant vaping (Unweighted n = 570)
<b>Age, years</b>			
18 to 24	33.2 (29.5–37.2)	17.2 (9.81–28.4)	18.3 (13.0–25.0)
25 to 44	41.2 (37.4–45.0)	59.6 (45.6–72.2)	47.7 (41.1–54.4)
45 to 69	23.7 (21.2–26.3)	19.7 (12.1–30.4)	30.7 (25.0–37.0)
70+	2.0 (1.5–2.7)	3.5 (0.9–12.9)	3.4 (1.9–5.8)
<b>Sex</b>			
Male	58.6 (54.9–62.3)	58.5 (43.4–72.2)	62.1 (55.4–68.4)
Female	41.3 (37.6–45.1)	41.4 (27.7–56.5)	37.9 (31.6–44.6)
<b>Race</b>			
Whites	71.5 (67.1–75.6)	54.0 (38.4–68.9)	55.9 (48.9–62.7)
Blacks	9.4 (6.9–12.8)	14.9 (5.9–32.7)	4.7 (2.5–8.4)
Hispanics	12.7 (9.3–17.2)	27.1 (13.9–46.1)	28.6 (22.3–36.0)
Other groups	6.4 (5.1–7.9)	4.0 (1.5–10.1)	10.8 (7.3–15.8)
<b>Highest education level</b>			
Less than high school diploma	12.7 (10.3–15.5)	10.2 (4.4–21.9)	5.0 (2.4–10.2)
High school diploma	39.6 (35.8–43.4)	16.4 (9.9–25.8)	24.3 (18.4–31.2)
Some college	47.8 (44.0–51.5)	73.4 (60.9–83.0)	70.8 (63.4–77.1)
<b>Federal poverty line ratio of household income</b>			
< 1	14.4 (12.1–17.1)	14.1 (7.3–25.5)	10.3 (6.7–15.3)
1–2	26.6 (23.2–30.2)	12.6 (6.7–22.4)	20.2 (15.1–26.4)
> 2	59.0 (55.2–62.7)	73.3 (60.4–83.1)	69.6 (62.8–75.6)
<b>Depression</b>	33.4 (30.1–37.0)	34.9 (23.3–48.6)	35.2 (28.8–42.3)
<b>BMI</b>			
Underweight	3.3 (2.2–4.8)	2.3 (0.9–5.4)	3.0 (1.4–6.6)
Normal weight	38.2 (34.6–42.0)	26.1 (16.1–39.6)	38.4 (32.1–45.2)
Overweight	32.4 (28.8–36.1)	37.4 (24.2–52.8)	30.8 (24.9–37.3)
Obese	26.2 (23.0–29.6)	34.2 (20.6–51.1)	27.8 (21.8–34.7)
<b>Smoking status</b>			
Never smoker	24.0 (20.7–27.6)	32.1 (21.0–45.7)	54.5 (47.8–61.1)
Current smoker	44.7 (41.0–48.4)	23.7 (14.7–35.9)	11.1 (7.9–15.4)
Former smoker	31.4 (28.0–35.0)	44.2 (29.5–60.0)	34.3 (28.3–41.0)

Results presented as % (95% confidence interval).

Dual vapers also had a greater proportion of Blacks compared to the other two populations.

Never and former smokers made up the majority of dual and

**Table 2**  
Association between sociodemographic and health factors, and patterns of vaping.

	Dual vaper (1) vs nicotine-pred. vaper (0)	P-value	Marijuana-pred. (1) vs nicotine-pred. vaper (0)	P-value
	OR (95% CI)		OR (95% CI)	
<b>Age</b>				
18 to 24	Ref		Ref	
25 to 44	3.44 (1.74–6.84)	0.000	4.76 (1.75–12.9)	0.002
45 to 69	2.74 (1.12–6.67)	0.027	5.23 (1.84–14.9)	0.002
70 +	7.31(1.65–32.5)	0.009	14.5 (3.74–55.9)	0.000
<b>Sex</b>				
Female	Ref		Ref	
Male	0.96 (0.50–1.84)	0.912	1.87 (1.19–2.93)	0.006
<b>Race</b>				
Whites	Ref		Ref	
Blacks	1.74 (0.62–4.91)	0.296	1.00 (0.40–2.52)	0.998
Hispanics	3.10 (1.18–8.13)	0.021	1.94 (0.48–7.93)	0.354
Other groups	0.88 (0.30–2.58)	0.811	0.55 (0.22–1.39)	0.206
<b>Education</b>				
Less than high school diploma	Ref		Ref	
High school diploma	0.46 (0.14–1.49)	0.195	0.45 (0.11–1.82)	0.265
Some college	1.40 (0.44–4.38)	0.567	0.94 (0.29–3.02)	0.912
<b>Federal poverty line ratio of household income</b>				
< 1	Ref		Ref	
“1–2”	0.31 (0.13–0.74)	0.009	2.26 (0.95–5.36)	0.064
> 2	1.03 (0.45–2.34)	0.948	2.37 (1.17–4.82)	0.017
Depression	1.22 (0.69–2.17)	0.494	1.85 (1.06–3.23)	0.031
<b>BMI</b>				
Underweight	Ref		Ref	
Normal weight	0.51 (0.16–1.68)	0.271	1.26 (0.31–5.22)	0.747
Overweight	0.78 (0.24–2.60)	0.691	0.78 (0.20–3.09)	0.727
Obese	0.79 (0.24–2.63)	0.705	1.37 (0.32–5.85)	0.672
<b>Smoking status</b>				
Current smoker	Ref		Ref	
Never smoker	3.77 (1.70–8.38)	0.001	17.7 (8.38–37.5)	0.000
Former smoker	2.54 (1.23–5.27)	0.012	3.35 (1.67–6.73)	0.001

OR = odds ratio, CI = confidence interval, Pred. = Predominant.

All models were adjusted for: age, sex, race, education, poverty level, clinical depression, BMI and smoking status.

marijuana-predominant vapers, whereas current smokers were preponderant among nicotine-predominant vapers. For instance, about half of marijuana-predominant vapers (54.5%) were never smokers, while close to half of nicotine-predominant vapers (44.7%) were current smokers.

Table 2 shows multivariable adjusted logistic regression analysis to assess the association between sociodemographic and health factors, and patterns of vaping. Dual vapers vs nicotine-predominant vapers: There is a significant association of dual vaping with increasing age, compared to nicotine-predominant vapers when adjusting for other covariates. For instance, compared to 18–24-year-olds, adults who are 24–44 and 45–69 years old have 3.44- and 2.74-times higher odds, respectively, to be dual vapers. Similarly, Blacks and Hispanics have higher odds to be dual vapers than Whites. When it comes to smoking, never and former smokers are significantly likely to be dual vapers compared to current smokers.

Marijuana-predominant vapers vs nicotine-predominant vapers: Older adults are more likely to be marijuana-predominant vapers than younger adults when adjusting for other covariates. Hispanics have higher odds to be marijuana-predominant vapers than Whites. Males are more likely than females to be marijuana-predominant vapers. Never smoking and former smoking are also highly associated with

marijuana-predominant vaping compared to current smoking.

Fig. 2 and Supplemental Table 1 shows the trends in prevalence of past 30-day marijuana use from 2016 to 2018 for the six states that provided marijuana data each year. There was a graded increase in any marijuana use across the US from 8.97% in 2016 to 13.1% in 2018 corresponding to an absolute increase of +4.18% in prevalence. Around the same period, prevalence of marijuana vaping decreased from 1.99% in 2016 to 1.13% in 2017 then followed by an increase to 1.63% in 2018. Repeating the analyses among all states that provided marijuana data show similar pattern of increase in the prevalence of any marijuana use and marijuana vaping. (Supplemental Table 1).

Among all states that provided marijuana data, there was a dip in the proportion of dual vapers among current e-cigarette users in 2017 to 2.6%, then followed by an increase in the proportion to 7.1% in 2018. Additionally, assessing in the six states that provided marijuana data for all 3 years showed a similar pattern of change in the proportion (Supplemental Table 1 and Supplemental Figure).

Table 3 shows the prevalence of marijuana vaping (dual and marijuana-predominant) among different sociodemographic groups for 2018. Prevalence was highest among adults aged 18–24 years (2.1%), corresponding to 640,000 marijuana vapers in the US. Prevalence was also high among males (1.7%), Hispanics (1.6%), and among former smokers (1.9%).

Supplemental Table 2 shows trends in prevalence of marijuana use by the six consistent states from 2016 to 2018 by individual state. The prevalence of any marijuana use varied by state, ranging from 8.49% in Wyoming to 14.9% in California in 2018. Similarly, prevalence of marijuana vaping also varied by state. Overall, prevalence of any marijuana use increased for all states from 2016 to 2018, despite varying legal statuses on marijuana use over the time period.

Supplemental Table 3 shows the US states and territories that provided marijuana data in BRFSS in 2016, 2017 and 2018. Supplemental Table 4 shows the legal statuses of marijuana use in the 16 states/territories of BRFSS 2018.

#### 4. Discussion

We describe the characteristics of nicotine and marijuana poly-use in e-cigarettes among US adults using the BRFSS, a large nationally representative survey. We report that 7.1% of current e-cigarette users also vape marijuana in 2018. We also report an increase in any marijuana use overall and in each of the six consistent states over this time period. The emerging population of marijuana vapers – including dual nicotine and marijuana vapers – on average are somewhat older, and more likely to be males, and never smokers compared to e-cigarette users who predominantly vape nicotine. Importantly, we also project that there are approximately 640,000 marijuana vapers (dual and marijuana-predominant) aged 18–24 years in the US in 2018.

Our estimates were generally similar across sociodemographic patterns, with greater e-cigarette use in all three groups among males, Whites, those with some college education, and those with family income greater than the poverty level. However, nicotine-predominant vapers were relatively younger than marijuana vapers (dual and predominant). This difference in age composition could be due to the tremendous rise in nicotine e-cigarette use in recent years, especially among youth and younger adults (Miech et al., 2019). This rise in e-cigarette use was partly contributed by aggressive marketing strategies of e-cigarette brands such as JUUL, which rose from 0% of US market share in 2016 to being the most dominant e-cigarette product in 2019 (Forbes, 2018; Huang et al., 2019; U.S. Food and Drug Administration, 2019).

We found marijuana vaping in 2018 to be more prevalent among younger adults compared to older. For instance, we report that the prevalence of marijuana vaping was the highest among 18–24 years of age (2.1%), compared to other age groups. Our findings are similar to that reported by Steigwald et al. in 2017 who reported the highest




Fig. 2. Trends in prevalence of past-30 day any marijuana use (yellow) and marijuana vaping (orange) from 2016 to 2018 for the six states that provided marijuana data each year. States: California, Idaho, Minnesota, Oklahoma, Tennessee, Wyoming. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

**Table 3**  
Prevalence (95% confidence interval) of past 30-day marijuana vaping (dual and marijuana-predominant) among different sociodemographic groups in the US, 2018.

	Marijuana vaping
Age, y	
18 to 24	2.1 (1.5–2.9)
25 to 44	2.0 (1.7–2.4)
45 to 69	0.9 (0.7–1.1)
70 +	0.3 (0.2–0.5)
Sex	
Male	1.7 (1.4–2.0)
Female	1.0 (0.8–1.2)
Race	
Whites	1.2 (1.1–1.5)
Blacks	0.8 (0.5–1.3)
Hispanics	1.6 (1.2–2.1)
Other groups	1.4 (0.9–2.0)
Highest education level	
Less than high school diploma	0.5 (0.3–0.9)
High school diploma	1.1 (0.8–1.5)
Some college	1.6 (1.4–1.8)
Federal Poverty Line Ratio of household income	
< 1	0.9 (0.6–1.3)
1–2	1.2 (0.9–1.6)
> 2	1.4 (1.2–1.6)
Depression	2.5 (2.0–3.1)
BMI	
Underweight	2.3 (1.1–4.5)
Normal weight	1.5 (1.3–1.9)
Overweight	1.2 (1.0–1.5)
Obese	1.3 (1.0–1.6)
Smoking status	
Never smoker	1.1 (0.9–1.3)
Current smoker	1.2 (0.9–1.5)
Former smoker	1.9 (1.5–2.3)

prevalence of marijuana vaping among the 18–34-year (8%) and 35–49-year (5.7%) age categories (Steigerwald et al., 2018). However, our prevalence estimates are smaller since we reported past 30-day use whereas they reported past-year use. In addition, similar to their findings, we found marijuana vaping prevalence to be highest among

Hispanics. While there has been an increase in marijuana use in multiple race/ethnicity groups including Hispanics in recent years (Substance Abuse and Mental Health Services Administration, 2017; Substance Abuse and Mental Health Services Administration, 2019), it is important to note the highest vaping prevalence in this group. However, there is limited data on marijuana use in e-cigarettes, more so by race/ethnicity groups. Further research will help explain potential determinants and implications of marijuana vaping in such groups.

E-cigarette use among never smokers (i.e. among those with no history of smoking traditional cigarettes) is concerning as it has been associated with increased transition to cigarette smoking among these adults (National Academies of Sciences, Engineering and M, 2018). Importantly, marijuana use has also been linked with cigarette smoking initiation (“reverse gateway effect”) (Weinberger et al., 2019). Thus it is concerning that 32.1% and 54.5% of dual vapers and marijuana-predominant vapers were never smokers, respectively, compared to 24% of nicotine-predominant vapers in our analysis, with implications for increased transition to cigarette smoking especially among the marijuana vapers. Additionally, a sizeable portion of these 2 sub-populations were current smokers (~24% and 11% of dual and marijuana-predominant vapers, respectively) which highlights greater polysubstance use in these 2 groups.

In our study, we report some of the most up to date data on dual nicotine and marijuana vaping, showing a decrease in the proportion of dual vapers among current e-cigarette users from 2016 to 2017 followed by an increase in 2018. There is, however, limited data on poly-use of nicotine and marijuana in e-cigarettes. In 2016, Kenne et al. observed that 7% (107/1524) of e-cigarette users in a university population reported other substance use in e-cigarettes, which is similar to our 2016 estimate of 8.6% (Kenne et al., 2017). While no clear trend was observed in our analysis, we speculate a possible increase in dual vaping among current e-cigarette users in upcoming years given the increased legalization of marijuana in the US. We additionally report that past 30-day marijuana use prevalence increased from 8.47% (2016) to 11.1% (2018) among all states that provided marijuana data. Similarly, a rise in marijuana use has also been reported by the National Survey on Drug Use and Health (NSDUH) with prevalence rising from 9.1%(2016) to 10.5% (2018) (Substance Abuse and Mental Health Services Administration, 2019).

Our study helps to quantify an important emerging pattern among e-cigarette use. Though our poly-use estimate of 7.1% in 2018 might

seem low, it is likely that poly-use of nicotine and marijuana in e-cigarettes will continue to expand in the future, given increasing legalization of marijuana and increase in e-cigarette use. In addition, poly-use has received significant attention because the 2019 EVALI outbreak involved many cases of e-cigarettes containing marijuana in addition to nicotine (Centers for Disease Control and Prevention, 2019). Blount et al. reported that vitamin E acetate, which is used as an additive in THC-containing e-cigarettes, was closely associated with EVALI (Blount et al., 2019). Due to the vast heterogeneity of devices and liquids used in e-cigarettes, it is generally difficult to identify any specific entity that is linked to all the respiratory cases. Concerningly, increasing poly-use would thus make it more challenging to tease out health effects of nicotine vs non-nicotine substances in e-cigarettes, posing a complex regulatory challenge for the FDA and other regulatory agencies. Additionally, a significant 38% of EVALI patients were 18 to 24 years old (Centers for Disease Control and Prevention, 2019). From our analysis, we project that there are approximately 640,000 marijuana vapers (dual and marijuana-predominant) aged 18–24 years of age in the US in 2018, who could be at a greater risk for EVALI compared to other age groups.

Our study has some limitations. All information in BRFSS, including e-cigarette and marijuana use data, was self-reported; biochemical confirmation was unavailable. Additionally, the cross-sectional, observational nature of the analyses would prevent making any causal associations between dual vaping and any sociodemographic factor. We also did not have data on the types of e-cigarette devices used to vape nicotine and marijuana. Also, our analysis focused among adults only. Future research focusing on youth and adolescents must also be a priority. While the 2017 and 2018 BRFSS included an interviewer's note for the e-cigarette questions to reliably capture nicotine use separate from marijuana use, this note was not included in 2016 BRFSS. Thus, some unmeasured non-nicotine use could have been captured. To account for some non-nicotine use, we therefore used the label 'predominant' which we think best captures current use patterns. Additionally, it is challenging to assess impact of state policies on trends in marijuana use. States that have the same state-level policy e.g. legalized medical marijuana, could still have important regulatory differences between them (Pacula et al., 2015). In addition, there is a heterogeneity in legislation approaches to marijuana use even among local jurisdictions within states (Ta et al., 2019). Thus, continued surveillance and further research, including detailed policy studies, are needed to assess impact of policies within and between states.

## 5. Conclusion

Given the limited data on poly-use in e-cigarettes, and the emerging epidemic of acute lung injury observed in such users, it is critical to thoroughly characterize this emerging population. We report that dual nicotine and marijuana vaping among adults using e-cigarettes is common (7.1%), and dual vapers are relatively older and less likely to use traditional cigarettes. Dual vaping is also higher among Blacks and Hispanics compared to nicotine vaping.

Our analysis reports up to date data on nicotine and marijuana vaping, which may be used to inform tobacco regulatory researchers, agencies and public health organizations about the emergence of poly-use in adult e-cigarette vapers, and may help guide future regulatory efforts and public health education campaigns to this potentially vulnerable population.

## Funding and acknowledgement

This research was supported in part by the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) and the FDA Center for Tobacco Products (CTP) under Awards P50HL120163 and U54HL120163. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the

manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the FDA or the American Heart Association.

## CRediT authorship contribution statement

**S. M. Iftekhar Uddin:**Conceptualization, Methodology, Formal analysis, Writing - original draft. **Albert D. Osei:**Conceptualization, Formal analysis, Writing - original draft. **Olufunmilayo H. Obisesan:**Formal analysis, Data curation, Writing - review & editing. **Omar El-Shahawy:**Formal analysis, Writing - review & editing. **Omar Dzaeye:**Data curation, Visualization. **Miguel Cainzos-Achirica:**Writing - review & editing, Project administration. **Mohammadhassan Mirbolouk:**Methodology, Data curation. **Olusola A. Orimoloye:**Methodology, Data curation, Writing - review & editing. **Andrew Stokes:**Methodology, Writing - review & editing. **Emelia J. Benjamin:**Conceptualization, Writing - review & editing. **Aruni Bhatnagar:**Conceptualization, Funding acquisition. **Andrew P. DeFilippis:**Conceptualization, Writing - review & editing. **Travis S. Henry:**Writing - review & editing. **Khurram Nasir:**Writing - review & editing. **Michael J. Blaha:**Conceptualization, Methodology, Supervision, Funding acquisition.

## Declaration of competing interest

Emelia J. Benjamin has received research grant from the NIH and American Heart Association (2U54HL120163). S. M. Iftekhar Uddin has received T32 grant from NIH (T32-HL-7227-44). All other authors have no financial disclosures or conflicts of interest.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ypmed.2020.106175>.

## References

- Basáñez, T., Majmundar, A., Cruz, T.B., Allem, J.P., Unger, J.B., 2019. E-cigarettes are being marketed as “Vitamin Delivery” devices. *Am. J. Public Health*. <https://doi.org/10.2105/AJPH.2018.304804>.
- Behavioral Risk Factor Surveillance System. Module Data for Analysis: 2016 BRFSS. 2016. [https://www.cdc.gov/brfss/annual\\_data/2016/pdf/2016moduleanalysis.pdf](https://www.cdc.gov/brfss/annual_data/2016/pdf/2016moduleanalysis.pdf).
- Behavioral Risk Factor Surveillance System. Weighting BRFSS Data - BRFSS 2018; 2018. [https://www.cdc.gov/brfss/annual\\_data/2018/pdf/weighting-2018-508.pdf](https://www.cdc.gov/brfss/annual_data/2018/pdf/weighting-2018-508.pdf).
- Behavioral Risk Factor Surveillance System (BRFSS). Complex Sampling Weights and Preparing 2018 BRFSS Module Data for Analysis.; 2019.
- Blount, B.C., Karwowski, M.P., Shields, P.G., et al., December 2019. Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMoa1916433>.
- CDC Health Alert Network. Severe Pulmonary Disease Associated with Using E-Cigarette Products. <https://emergency.cdc.gov/han/han00421.asp>. Published 2019.
- Centers for Disease Control and Prevention, 2019. Outbreak of lung injury associated with E-cigarette use, or vaping. In: *Outbreak of Lung Injury Associated with E-Cigarette Use, or Vaping*. Published.
- Forbes. The Disturbing Focus of Juul's Early Marketing Campaigns. [forbes.com/sites/kathleenchaykowski/2018/11/16/the-disturbing-focus-of-juuls-early-marketing-campaigns/#6f808aed14f9](https://forbes.com/sites/kathleenchaykowski/2018/11/16/the-disturbing-focus-of-juuls-early-marketing-campaigns/#6f808aed14f9). Published 2018.
- Huang, J., Duan, Z., Kwok, J., et al., 2019. Vaping versus JUULing: how the extraordinary growth and marketing of JUUL transformed the US retail e-cigarette market. *Tob. Control*. <https://doi.org/10.1136/tobaccocontrol-2018-054382>.
- Kenne, D.R., Fischbein, R.L., Tan, A.S.L., Banks, M., 2017. The use of substances other than nicotine in electronic cigarettes among college students. *Subst Abuse Res Treat*. <https://doi.org/10.1177/1178221817733736>.
- Layden, J.E., Ghinai, I., Pray, I., et al., 2019. Pulmonary illness related to E-cigarette use in Illinois and Wisconsin — preliminary report. *N. Engl. J. Med.* <https://doi.org/10.1056/nejmoa1911614>.
- Maddock, S.D., Cirulis, M.M., Callahan, S.J., et al., 2019. Pulmonary lipid-laden macrophages and vaping. *N. Engl. J. Med.* <https://doi.org/10.1056/nejmc1912038>.
- Miech, R., Johnston, L., O'Malley, P.M., Bachman, J.G., Patrick, M.E., 2019. Trends in adolescent vaping, 2017–2019. *N. Engl. J. Med.* <https://doi.org/10.1056/nejmc1910739>.
- Mirbolouk, M., Charkhchi, P., Kianoush, S., et al., 2016. Prevalence and distribution of e-cigarette use among U.S. adults: behavioral risk factor surveillance system. *Ann. Intern. Med.* 2018. <https://doi.org/10.7326/M17-3440>.

- National Academies of Sciences, Engineering and M. Public Health Consequences of E-Cigarettes. Washington, DC; 2018.
- National KIDS COUNT. Adult Population by Age Group in the United States. <https://datacenter.kidscount.org/data/tables/6538-adult-population-by-age-group?loc=1&loct=1#detailed/1/any/false/37/117/13515,13516>. Published 2019. January 12, 2019.
- Office of the Surgeon General. E-Cigarette use Among Youth and Young Adults: A Report of the Surgeon General. Washington, DC; 2016. <https://e-cigarettes.surgeongeneral.gov/>.
- Pacula, R.L., Powell, D., Heaton, P., Sevigny, E.L., 2015. Assessing the effects of medical marijuana laws on marijuana use: the devil is in the details. *J Policy Anal Manag.* <https://doi.org/10.1002/pam.21804>.
- Steigerwald, S., Wong, P.O., Cohen, B.E., et al., 2018. Smoking, vaping, and use of edibles and other forms of marijuana among U.S. adults. *Ann. Intern. Med.* <https://doi.org/10.7326/M18-1681>.
- Substance Abuse and Mental Health Services Administration, 2017. 2016 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD. <https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf>.
- Substance Abuse and Mental Health Services Administration, 2019. Results from the 2018 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD. <https://www.samhsa.gov/data/report/2018-nsduh-detailed-tables>.
- Ta, M., Greto, L., Bolt, K., 2019. Trends and characteristics in marijuana use among public school students - King County, Washington, 2004-2016. *MMWR Morb. Mortal. Wkly Rep.* <https://doi.org/10.15585/mmwr.mm6839a3>.
- U.S. Census Bureau. QuickFacts. <https://www.census.gov/quickfacts/fact/table/US/PST045218#PST045218>. Published 2018. January 12, 2019.
- U.S. Department of Health & Human Services. 2018 Poverty Guidelines. <https://aspe.hhs.gov/2018-poverty-guidelines>. Published 2018. January 1, 2019.
- U.S. Food and Drug Administration. FDA Warns JUUL Labs for Marketing Unauthorized Modified Risk Tobacco Products, Including in Outreach to Youth. <https://www.fda.gov/news-events/press-announcements/fda-warns-juul-labs-marketing-unauthorized-modified-risk-tobacco-products-including-outreach-youth>. Published 2019.
- Weinberger, A.H., Delnevo, C.D., Wyka, K., et al., 2019. Cannabis use is associated with increased risk of cigarette smoking initiation, persistence, and relapse among adults in the United States. *Nicotine Tob. Res.* <https://doi.org/10.1093/ntr/ntz085>.